<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05704803</url>
  </required_header>
  <id_info>
    <org_study_id>3EO-CoV2-02</org_study_id>
    <nct_id>NCT05704803</nct_id>
  </id_info>
  <brief_title>COVID-19 Molecular OTC At Home Test</brief_title>
  <official_title>Prospective, Multi-Center, Non-Randomized Study to Evaluate OTC At Home SARS-CoV-2 Molecular Diagnostic Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3EO Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3EO Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the a molecular, OTC/At-Home COVID-19 Test in&#xD;
      individuals presenting at a medical facility. In eligible subjects, nasal samples will be&#xD;
      collected for use with the at-home molecular COVID-19 Test, which will be compared to the&#xD;
      Zymo® rRT-PCR test results obtained via samples specified by the sponsor (e.g., AN [anterior&#xD;
      nares] swab) to determine accuracy of the at-home/OTC molecular COVID-19 Test in detecting&#xD;
      COVID-19 in participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The molevular, at-home COVID-19 Test is a unique rapid molecular test system intended to&#xD;
      detect SARS-CoV-2 virus in the OTC setting using a dedicated reusable test reader to test&#xD;
      nasal swab samples. Early testing will help to determine limit of detection (LOD) of the&#xD;
      molecular COVID-19 Test and will be compared to a sensitive molecular test that has been&#xD;
      authorized for emergency use by the FDA. The COVID-19 Test will leverage the processing and&#xD;
      testing of the associated Swab device when inserted directly into the reaction tube (Key)&#xD;
      where reverse transcription, Loop-Mediated Isothermal DNA Amplifications (LAMP) processing&#xD;
      and sequence-specific probe technologies to detect segments of the SARS-CoV-2 genome are&#xD;
      managed automatically by the reusable test reader.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2023</start_date>
  <completion_date type="Anticipated">August 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of the 3EO Health SARS-CoV-2 standard of care (PCR) Zymo rRT-PCR results of the anterior nare sample.</measure>
    <time_frame>1-16 weeks</time_frame>
    <description>The primary endpoints of this study will be the correlation of the 3EO Health SARS-CoV-2 OTC At Home Test results from nasal samples to the comparator, standard of care (PCR) Zymo rRT-PCR results of the anterior nare sample</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>COVID-19 Pandemic</condition>
  <arm_group>
    <arm_group_label>Study Groups</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Positives: Symptomatic vs. Asymptomatic Negatives: Symptomatic vs. Asymptomatic&#xD;
Each broken down by age groups:&#xD;
2-14 years old 15-24 years old 25-64 years old 65+ years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic Test: IN Vitro</intervention_name>
    <description>In vitro diagnostic test for COVID-19 using anterior nasal swabs.</description>
    <arm_group_label>Study Groups</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        All Participants must meet ALL of the following:&#xD;
&#xD;
          1. ≥ 2 years of age. Subjects ages 2 ≤ x ≤ 17 will provide assent in addition to parent /&#xD;
             legal guardian's consent.&#xD;
&#xD;
          2. Able to read and write in English and/or Spanish (subjects or guardians)&#xD;
&#xD;
          3. Willing and able to provide informed consent (subject or Legally authorized&#xD;
             Representative (LAR)). Subjects unable to consent will provide assent in addition to&#xD;
             LAR consent.&#xD;
&#xD;
        Symptomatic Participants must meet BOTH of the following:&#xD;
&#xD;
          1. Have at least one of the following symptoms the day of the test:&#xD;
&#xD;
               1. Fever&#xD;
&#xD;
               2. Cough&#xD;
&#xD;
               3. Shortness of Breath&#xD;
&#xD;
               4. Difficulty Breathing&#xD;
&#xD;
               5. Muscle Pain&#xD;
&#xD;
               6. Headache&#xD;
&#xD;
               7. Sore Throat&#xD;
&#xD;
               8. Chills&#xD;
&#xD;
               9. New loss of taste or smell&#xD;
&#xD;
              10. Congestion&#xD;
&#xD;
              11. Runny nose&#xD;
&#xD;
          2. Onset of symptoms occurred within the past 7 calendar days.&#xD;
&#xD;
        Asymptomatic Participants must meet BOTH of the following:&#xD;
&#xD;
          1. Not experiencing any of the following symptoms at the time of specimen collection and&#xD;
             testing: fever, cough, shortness of breath or difficulty breathing, new loss of taste&#xD;
             or smell, muscle or body aches, headache, sore throat, congestion or runny nose,&#xD;
             nausea or vomiting or diarrhea.&#xD;
&#xD;
          2. Exposed to known COVID-19 positive individuals or are suspected to have had COVID-19&#xD;
             over the past 7 calendar days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants must not meet ANY of the following:&#xD;
&#xD;
          1. Eating or drinking 30 minutes prior, or smoking 60 minutes prior to specimen&#xD;
             collection.&#xD;
&#xD;
          2. Unable to tolerate sample collection, or has contraindications to collection such as&#xD;
             nasal bleeding, ulcers, or surgery within the past 3 months.&#xD;
&#xD;
          3. Underwent a nasal wash / aspirate as part of standard of care &lt; 24 hours prior to the&#xD;
             study start.&#xD;
&#xD;
          4. Currently receiving or has received within the past 30 days of the study visit an&#xD;
             experimental drug, biologic, or device including treatment or therapy.&#xD;
&#xD;
          5. Previously participated in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adelina Paunescu, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medicept Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis P Shay, PhD</last_name>
    <phone>9788461247</phone>
    <email>dshay@3eohealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bright Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Mendez-Mulet, MD</last_name>
      <phone>786-870-5487</phone>
    </contact>
    <contact_backup>
      <last_name>Sukie Hernandez</last_name>
      <phone>786-870-5487</phone>
      <email>shernendez@brclinical.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>I.V.A.M. Clinical &amp; Investigational Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Curbelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vytalus Medical Atascocita</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Sepulveda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vytalus Medical</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Basaldua, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcus Sevier, PAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2023</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

